Wnt signalling and prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 2, 2005, Pages 119-126

  Yardy, George W ^a,b   Brewster, S F ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

catenin; Wnt signalling

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; TRANSACTIVATOR PROTEIN;

CANCER THERAPY; CELL POPULATION; DRUG TARGETING; EMBRYO DEVELOPMENT; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; URINARY TRACT CANCER; BIOSYNTHESIS; CELL TRANSFORMATION; GENETICS; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; CYTOSKELETAL PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; WNT PROTEINS;

EID: 23944456470     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500794     Document Type: Review

References (103)

1. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998; 14: 59-88.
2. Yang-Snyder J et al. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr Biol 1996; 6: 1302-1306.
3. Noordermeer J, Klingensmith J, Perrimon N, Nusse R. Dishevelled and armadillo act in the wingless signalling pathway in Drosophila. Nature 1994; 367: 80-83.
4. Fagotto F et al. Domains of axin involved in protein-protein interactions, Wnt pathway inhibition, and intracellular localization. J Cell Biol 1999; 145: 741-756.
5. Willert K, Shibamoto S, Nusse R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev 1999; 13: 1768-1773.
6. Bodmer WF et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987; 328: 614-616.
7. Trent JM et al. The gene for the APC-binding protein beta-catenin (CTNNB1) maps to chromosome 3p22, a region frequently altered in human malignancies. Cytogenet Cell Genet 1995; 71: 343-344.
8. Ikeda S et al. GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene 2000; 19: 537-545.
9. Ikeda S et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3 beta-dependent phosphorylation of beta-catenin. EMBO J 1998; 17: 1371-1384.
10. Chesire DR, Isaacs WB. Beta-catenin signaling in prostate cancer: An early perspective. Endocrine Related Cancer 2003; 10: 537-560.
11. Dajani R et al. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J 2003; 22: 494-501.
12. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001; 10: 721-733.
13. Lee E et al. The roles of APC and axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol 2003; 1: E10.
14. Dong X et al. Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene. Cytogenet Cell Genet 2001; 93: 26-28.
15. Behrens J et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998; 280: 596-599.
16. Kobayashi M et al. Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer 2000; 82: 1689-1693.
17. Roose J, Clevers H. TCF transcription factors: Molecular switches in carcinogenesis. Biochim Biophys Acta 1999; 1424: M23-M37.
18. He TC et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
19. Mann B et al. Target genes of beta-catenin-T cell-factor/ lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999; 96: 1603-1608.
20. Crawford HC et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999; 18: 2883-2891.
21. Marchenko ND et al. Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol 2004; 36: 942-956.
22. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
23. Wiechens N et al. Nucleo-cytoplasmic shuttling of Axin, a negative regulator of the Wnt-beta-catenin Pathway. J Biol Chem 2004; 279: 5263-5267.
24. Cong F, Varmus H. Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of {beta}-catenin. Proc Natl Acad Sci USA 2004; 101: 2882-2887.
25. Leung JY et al. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem 2002; 277: 21657-21665.
26. Lustig B et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002; 22: 1184-1193.
27. Playford MP et al. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 2000; 97: 12103-12108.
28. Desbois-Mouthon C et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001; 20: 252-259.
29. Monick MM et al. Ceramide regulates lipopolysaccharide-induced phosphatidylinositol 3-kinase and Akt activity in human alveolar macrophages. J Immunol 2001; 167: 5977-5985.
30. Matsuzawa SI, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 2001; 7: 915-926.
31. Liu J et al. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001; 7: 927-936.
32. Iwai A et al. Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates beta-catenin activity in a p53-dependent manner. Oncogene 2004; 23: 7593-7600.
33. Deng J et al. Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2002; 2: 323-334.
34. Deng J et al. Crossregulation of NF-kappaB by the APC/GSK3beta/ beta-catenin pathway. Mol Carcinog 2004; 39: 139-146.
35. Nastasi T et al. Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis. Dev Cell 2004; 6: 269-282.
36. Seeling JM et al. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 1999; 283: 2089-2091.
37. Hsu W, Zeng L, Costantini F. Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem 1999; 274: 3439-3445.
38. Easwaran V, Pishvaian M, Salimuddin, Byers S. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 1999; 9: 1415-1418.
39. Tice DA et al. Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J Biol Chem 2002; 277: 14329-14335.
40. Liu T, Lee YN, Malbon CC, Wang HY. Activation of the beta-catenin/ Lef-Tcf pathway is obligate for formation of primitive endoderm by mouse F9 totipotent teratocarcinoma cells in response to retinoic acid. J Biol Chem 2002; 277: 30887-30891:
41. Xiao JH et al. Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway, J Biol Chem 2003; 278: 29954-29962.
42. Rother K et al. Identification of Tcl-4 as a transcriptional target of p53 signalling. Oncogene 2004; 23: 3376-3384.
43. Levina E, Oren M, Ben-Ze'ev A. Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics. Oncogene 2004; 23: 4444-4453.
44. Oloumi A, McPhee T, Dedhar S. Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta 2004; 1691: 1-15.
45. Park CS et al. Modulation of beta-catenin phosphorylation/degradation by cyclin-dependent kinase 2. J Biol Chem 2004; 279: 19592-19599.
46. Kim SI et al. Cyclin-dependent kinase 2 regulates the interaction of Axin with beta-catenin. Biochem Biophys Res Commun 2004; 317: 478-483.
47. Morin PJ et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
48. Powell SM et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-237.
49. Asman HB, Pierce ER. Familial multiple polyposis. A statistical study of a large Kentucky kindred. Cancer 1970; 25: 972-981.
50. Korinek V et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275: 1784-1787.
51. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 1130-1134.
52. Ilyas M et al. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 1997; 94: 10330-10334.
53. Fukuchi T et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998; 58: 3526-3528.
54. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998; 58: 1344-1347.
55. Park WS et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999; 59: 4257-4260.
56. Miyoshi Y et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998; 58: 2524-2527.
57. Sunaga N et al. Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 2001; 30: 316-321.
58. Rubinfeld B et al. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790-1792.
59. Rimm DL et al. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999; 154: 325-329.
60. Satoh S et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24: 245-250.
61. Taniguchi K et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21: 4863-4871.
62. Koppert LB et al. Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear beta-catenin expression. Br J Cancer 2004; 90: 892-899.
63. Dahmen RP et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 2001; 61: 7039-7043.
64. Baeza N, Masuoka J, Kleihues P, Ohgaki H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 2003; 22: 632-636.
65. Liu W et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 2000; 26: 146-147.
66. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001; 61: 8247-8255.
67. Watcharasit P et al. Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci USA 2002; 99: 7951-7955.
68. Kim HS et al. Regulation of angiogenesis by glycogen synthase kinase-3beta. J Biol Chem 2002; 277: 41888-41896.
69. Brewster SF, Browne S, Brown KW. Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. J Urol 1994; 151: 1073-1077.
70. Phillips SM et al. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol 1994; 73: 390-395.
71. Watanabe M et al. APC gene mutations in human prostate cancer. Jpn J Clin Oncol 1996; 26: 77-81.
72. Suzuki H et al. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jpn J Cancer Res 1994; 85: 847-852.
73. Davies G, Jiang WG, Mason MD. Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells. J Urol 2000; 163: 985-992.
74. Bryden AA et al. E-cadherin and beta-catenin are down-regulated in prostatic bone metastases. Br J Urol Int 2002; 89: 400-403.
75. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58: 2520-2523.
76. Gerstein AV et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002; 34: 9-16.
77. Chesire DR et al. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2600; 45: 323-334.
78. Chesire DR, Ewing CM, Gage W-R, Isaacs WB. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002; 21: 2679-2694.
79. de la Taille A et al. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 2003; 9: 1801-1807.
80. Chen G et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications. Cancer 2004; 101: 1345-1356.
81. Gounari F et al. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 2002; 21: 4099-4107.
82. Culig Z et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998; 35: 63-70.
83. Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60: 4709-4713.
84. Yang F et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002; 277: 11336-11344.
85. Pawlowski JE et al. Liganded androgen receptor interaction with beta-catenin: Nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 2002; 277: 20702-20710.
86. Mulholland DJ et al. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 2002; 277: 17933-17943.
87. Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. T cell factor. Oncogene 2002; 21: 8453-8469.
88. Mulholland DJ et al. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: A means for inhibition of the Tcf signaling axis. Oncogene 2003; 22: 5602-5613.
89. Linja MJ et al. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004; 10: 1032-1040.
90. Li P, Nicosia SV, Bai W. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 2001; 276: 20444-20450.
91. Wen Y et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 6841-6845.
92. Sharma M, Chuang W-W, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 2002; 277: 30935-30941.
93. Willett WC. Micronutrients and cancer risk. Am J Clin Nutr 1994; 59: 1162S-1165S.
94. Jaszewski R et al. Folic acid reduces nuclear translocation of beta-catenin in rectal mucosal crypts of patients with colorectal adenomas. Cancer Lett 2004; 206: 27-33.
95. Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 1999; 190: 445-450.
96. Smith ML, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: Evidence of different mechanisms of action. Eur J Cancer 2000; 36: 664-674.
97. Diblmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/ TCF-4 signaling. Oncogene 2001; 20: 645-653.
98. Gardner SH, Hawcroft G, Hull MA. Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer 2004; 91: 153-163.
99. Boon EM et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004; 90: 224-229.
100. Lepourcelet M et al. Small-molecule antagonists of the oncogenic Tcf/ beta-catenin protein complex. Cancer Cell 2004; 5: 91-102.
101. Emami KH et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proc Natl Acad Sci USA 2004; 101: 12682-12687.
102. Karaguni IM et al. SMAF-1 inhibits the APC/beta-catenin pathway and shows properties similar to those of the tumor suppressor protein APC. Chembiochem 2004; 5: 1267-1270.
103. Kwong KY, Zou Y, Day CP, Hung MC. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. Oncogene 2002; 21: 8340-8346.